Jeremy Parsons, MD
Clinical Pathology/Laboratory Medicine · Albuquerque, NMNPI 1427254572
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,853 of the $4,010 with a category attached, or 71.1%. Grifols, S.A. accounts for 95.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2020 at $2,600 and has fallen 98.4% since, to $42 in 2025.
Across 14 payments — averaging $286.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols, S.A.$4K
- Daiichi Sankyo Inc.$46
- Pharmacosmos Therapeutics Inc.$42
- Jazz Pharmaceuticals Inc.$29
- AbbVie$18
- Biohaven Pharmaceuticals, Inc.$17
- plus $29 from 2 others
Across 6 payments — averaging $17,365 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Grifols Diagnostic Solutions, Inc.$104K
What the payments were for
- Speaking & faculty fees$2,85371%
- Travel & lodging$97624%
- Food & beverage$1815%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols, S.A. | 5 | $3,829 |
| Daiichi Sankyo Inc. | 3 | $46 |
| Pharmacosmos Therapeutics Inc. | 1 | $42 |
| Jazz Pharmaceuticals Inc. | 1 | $29 |
| AbbVie | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Amgen | 1 | $16 |
| Grifols USA, LLC | 1 | $13 |
How this compares
Too few clinical pathology/laboratory medicine providers in New Mexicoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 21 | $13,425 |
| Alendronate Sodium | 18 | $294 |
Paid to pharmacies, not to this prescriber.
Other clinical pathology/laboratory medicine in Albuquerque
- James ElliottAlbuquerque$230K
- Nancy JosteAlbuquerque$6K
- Evelyn LockhartAlbuquerque$3K
- Mary FoucarAlbuquerque$1K
- Lizabeth MarinaroAlbuquerque$306
- Matthew LukeAlbuquerque$245
- Carla WilsonAlbuquerque$231
- Mary TorrezAlbuquerque$93
- Edgar FischerAlbuquerque$46
- Joseph GlassAlbuquerque$23
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.